SOURCE: BioMedReports


March 28, 2011 07:01 ET

Expert Briefing: Treating Skeletal Muscle Injuries With Pluristem's PLacental eXpanded (PLX) Cells

LOS ANGELES, CA--(Marketwire - March 28, 2011) -  An Expert Briefing by William R. Prather RPh, MD, the Senior VP Corporate Development at Pluristem Therapeutics, Inc. (NASDAQ: PSTI) (TASE: PLTR), has been published for biotech investors, doctors and other interested medical personnel.

Injuries to muscle are common. It has been reported that skeletal muscles are involved in up to 55% of all injuries sustained in sports.

In the United States, strains (tears) of the adductors, hip flexors, quadriceps, pectoral and hamstring muscles account for more than a million office visits to doctors every year. On the job, leg strains, sprains and tears are the second most common type of work-related injury in American adults, with approximately 100,000 cases reported annually to the U.S. Bureau of Labor Statistics.

In contrast to the unintentional muscle injury market, the intentional muscle injury market comprises those patients who, post-operatively, have potential weaknesses to the skeletal muscles. For example, it has been estimated that an incisional hernia will develop in approximately 10-15% of abdominal incisions. With more than 4 million abdominal surgeries performed in the United States every year, this translates into approximately 500,000 incisional hernias annually in the U.S. alone.

Recovery time for muscle injuries can range from a few days to several weeks depending on the muscle involved and the severity of the tear. There are however, other treatments that are currently undergoing testing that may significantly alter the way muscle injuries are treated.

One such treatment is being developed by Pluristem Therapeutics, the Israel-based biotechnology company developing cell therapies derived from the human placenta. The company recently announced the results of a pre-clinical animal study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This study suggests that Pluristem's PLX cells have the potential to treat various types of accidental and intentionally induced muscle injuries.

The full special report about Pluristem's patented mesenchymal stromal cell-like product, PLX is now available at :

Investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556